Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berlim 25/10 in T2DM and Dyslipidemia
NCT04603508Phase 3Unknown
- Sponsor
- EMS
- Start
- Mar 2023
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, triple-blind trial of empagliflozin and rosuvastatin in type 2 diabetes mellitus (T2DM) and dyslipidemia, sponsored by EMS. Primary endpoints: Change from baseline in glycated hemoglobin (HbA1c) levels at 120 days and Percent change from baseline of LDL-c levels at 120 days. Status: unknown.
02
Drugs
empagliflozinrosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT04603508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603508.